SEGMENTATION QUICK REFERENCE
| Dimension | Sub-Segments | Dominant Segment | Fastest Growing Segment |
| Technology | PCR, IHC, NGS, ISH, Others | Polymerase Chain Reaction (PCR) | Next-Generation Sequencing (NGS) |
| Indication | Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Others | Lung Cancer | Melanoma |
| Product Type | Assays and Kits, Instruments and Analyzers, Software and Services | Assays and Kits | Software and Services |
| Sample Type | Tissue Biopsy, Liquid Biopsy, Others | Tissue Biopsy | Liquid Biopsy |
| End User | Pharma & Biotech Companies, CROs, Hospitals & Reference Labs, Academic & Research Institutions | Pharmaceutical & Biotechnology Companies | Contract Research Organizations (CROs) |
MARKET SEGMENTATION OVERVIEW
By Technology
| Sub-Segment | Key Trend |
| Polymerase Chain Reaction (PCR) | Entrenched in community labs for single-gene CDx; mature but stable demand |
| Immunohistochemistry (IHC) | Core platform for HER2 and PD-L1 protein expression testing |
| Next-Generation Sequencing (NGS) | Rapid adoption of multi-gene panels; declining per-sample costs driving expansion |
| In Situ Hybridization (ISH) | Essential for gene rearrangement detection (ALK, ROS1); steady utilization |
| Others | Emerging modalities including ddPCR and mass spectrometry gaining niche traction |
PCR and IHC remain the foundational technologies in companion diagnostics, but the transition toward NGS-based comprehensive genomic profiling is accelerating as reimbursement pathways mature and clinical guidelines increasingly mandate multi-gene testing upfront.
By Indication
| Sub-Segment | Key Trend |
| Lung Cancer | Largest indication; nine or more actionable targets mandate molecular testing |
| Breast Cancer | HER2, BRCA1/2, and PIK3CA testing anchor treatment selection |
| Colorectal Cancer | RAS/BRAF panels guide anti-EGFR therapy decisions |
| Melanoma | BRAF/MEK combination therapies expanding into adjuvant settings |
| Other Indications | Hematologic malignancies, urothelial cancer, and rare tumors driving incremental growth |
Oncology dominates companion diagnostic indications, with lung and breast cancer accounting for the majority of testing volume. Melanoma and emerging tumor types represent the fastest-growing indication categories as new targeted therapies gain regulatory approval.
By Product Type
| Sub-Segment | Key Trend |
| Assays and Kits | Captive demand driven by drug-label requirements; dominant revenue source |
| Instruments and Analyzers | Platform refresh cycles and emerging multi-omic analyzers |
| Software and Services | AI-driven interpretation and data management platforms growing fastest |
Assays and kits will continue to generate the bulk of companion diagnostic revenues due to their direct linkage with drug approvals, while software platforms represent a high-growth overlay that adds recurring revenue to the traditional consumables model.
By Sample Type
| Sub-Segment | Key Trend |
| Tissue Biopsy | Remains the regulatory gold standard for histological confirmation |
| Liquid Biopsy | Non-invasive blood-based testing gaining first-line clinical acceptance |
| Other Sample Types | Bone marrow and cytology specimens for hematologic and rare-tumor applications |
Tissue biopsy dominates current clinical workflows, but liquid biopsy is positioned for rapid share gains as prospective outcome studies validate blood-based testing for treatment selection and monitoring.
By End User
| Sub-Segment | Key Trend |
| Pharmaceutical & Biotechnology Companies | Primary funders of CDx co-development programs |
| Contract Research Organizations (CROs) | Fastest-growing end user as pharma outsources CDx validation |
| Hospitals & Reference Laboratories | Core clinical testing sites with growing molecular capabilities |
| Academic & Research Institutions | Translational research and biomarker discovery pipelines |
Pharmaceutical companies drive the largest share of end-user demand through co-development investments, while CROs are capturing an increasing proportion of the development and validation workflow as the complexity and regulatory burden of CDx programs grow.
